Trial Profile
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BOOST
- Sponsors Novo Nordisk
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2018 Primary endpoint (Change from baseline in HbA1c (%) (glycosylated haemoglobin)) has been met, according to results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2018 Results (n=541) presented at the 78th Annual Scientific Sessions of the American Diabetes Association.